International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Journal of Thrombosis and Haemostasis - Tập 4 Số 2 - Trang 295-306 - 2006
Spiros Miyakis1, Michael D. Lockshin2, Tatsuya Atsumi3, D. Ware Branch4, Robin L. Brey5, Ricard Cervera6, R. H. W. M. Derksen7, Philip G. de Groot7, Takayoshi Koike3, Pier Luigi Meroni8, Guido Reber9, Søren Jacobsen10, Anǵela Tincani11, Panayiotis G. Vlachoyiannopoulos12, Steven A. Krilis1
1St George Hospital, University of New South Wales, Sydney, Australia
2Hospital for Special Surgery, Cornell Medical Center, New York, NY, USA
3Hokkaido Univ., Sapporo, Japan
4University of Utah Health Sciences Center, Salt Lake City, UT
5University of Texas Health Science Center, San Antonio, TX USA
6Hospital Clinic, Barcelona, Spain
7University Medical Center, Utrecht, The Netherlands
8Istituto Auxologico Italiano, University of Milan, Milan, Italy
9#N# #N# University Hospital Geneva, Switzerland
10Sheba Medical Center, Tel-Hashomer and Tel Aviv University, Israel
11Spedali Civili, University of Brescia, Italy
12Department of Pathophysiology, University of Athens, Greece

Tóm tắt

Từ khóa


Tài liệu tham khảo

Wilson, 1999, International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop, Arthritis Rheum, 42, 1309, 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F

Lockshin, 2000, Validation of the Sapporo criteria for antiphospholipid syndrome, Arthritis Rheum, 43, 440, 10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N

Weber, 2001, The Sapporo criteria for antiphospholipid syndrome: comment on the article by Lockshin et al, Arthritis Rheum, 44, 1965, 10.1002/1529-0131(200108)44:8<1965::AID-ART338>3.0.CO;2-9

Cooper, 2000, Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention, Circulation, 102, 3137, 10.1161/01.CIR.102.25.3137

Chobanian, 2003, Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2

Walker, 2001, Haemostasis and thrombosis task force, British Committee for standards in haematology. Investigation and management of heritable thrombophilia, Br J Haematol, 114, 512, 10.1046/j.1365-2141.2001.02981.x

Genvresse, 2002, Prevalence and clinical significance of anticardiolipin and anti‐beta2‐glycoprotein‐I antibodies in patients with non‐Hodgkin's lymphoma, Eur J Haematol, 68, 84, 10.1034/j.1600-0609.2002.01526.x

Lee, 2003, Anticardiolipin and anti‐beta2‐glycoprotein‐I antibodies in preeclampsia, Obstet Gynecol, 102, 294

Branch, 2001, Antiphospholipid antibodies in women at risk for preeclampsia, Am J Obstet Gynecol, 184, 825, 10.1067/mob.2001.113846

Sebire, 2003, Placental pathology, antiphospholipid antibodies, and pregnancy outcome in recurrent miscarriage patients, Obstet Gynecol, 101, 258

2002

Branch, 1989, The association of antiphospholipid antibodies with severe preeclampsia, Obstet Gynecol, 73, 541

Levine, 2002, The antiphospholipid syndrome, N Engl J Med, 346, 752, 10.1056/NEJMra002974

Wong, 2004, Consensus guidelines for anticardiolipin antibody testing, Thromb Res, 114, 559, 10.1016/j.thromres.2004.06.002

Harris, 1986, Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test, Arch Intern Med, 146, 2153, 10.1001/archinte.1986.00360230069012

Finazzi, 1996, Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four‐year prospective study from the Italian Registry, Am J Med, 100, 530, 10.1016/S0002-9343(96)00060-5

Lynch, 1994, Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study, Ann Intern Med, 120, 470, 10.7326/0003-4819-120-6-199403150-00004

Tincani, 2004, Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies, Thromb Res, 114, 553, 10.1016/j.thromres.2004.06.035

Levine, 1997, IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo‐occlusive events and death. A prospective cohort study, Stroke, 28, 1660, 10.1161/01.STR.28.9.1660

Neville, 2003, Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies, Thromb Haemost, 90, 108, 10.1055/s-0037-1613606

Obermoser, 2004, Clinical significance of anticardiolipin and anti‐beta2‐glycoprotein I antibodies, Int Arch Allergy Immunol, 135, 148, 10.1159/000080658

Detkova, 1999, Do antibodies to beta2‐glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome, Lupus, 8, 430, 10.1177/096120339900800604

Lee, 2003, Does the anti‐beta2‐glycoprotein I antibody provide additional information in patients with thrombosis, Thromb Res, 111, 29, 10.1016/j.thromres.2003.08.023

Derksen, 2004, Real world experience with antiphospholipid antibodies (aPL): How stable are aPL over time, Arthritis Rheum, 50, S67

Topping, 1999, Marked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome, Hum Reprod, 14, 224, 10.1093/humrep/14.1.224

Salazar‐Paramo, 2002, Longitudinal study of antinuclear and anticardiolipin antibodies in pregnant women with systemic lupus erythematosus and antiphospholipid syndrome, Rheumatol Int, 22, 142, 10.1007/s00296-002-0207-x

McClain, 2004, The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus, Arthritis Rheum, 50, 1226, 10.1002/art.20120

Male, 2005, Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus, Blood, 106, 4152, 10.1182/blood-2005-05-2048

Vianna, 1994, Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients, Am J Med, 96, 3, 10.1016/0002-9343(94)90108-2

Salmon, 2002, Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis, Ann Rheum Dis, 61, ii46, 10.1136/ard.61.suppl_2.ii46

Girardi, 2004, Heparin prevents antiphospholipid antibody‐induced fetal loss by inhibiting complement activation, Nat Med, 10, 1222, 10.1038/nm1121

Asherson, 2003, Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines, Lupus, 12, 530, 10.1191/0961203303lu394oa

Cervera, 2002, Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients, Arthritis Rheum, 46, 1019, 10.1002/art.10187

Turiel, 2000, Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography, Lupus, 9, 406, 10.1191/096120300678828532

Galve, 1992, Valvular heart disease in the primary antiphospholipid syndrome, Ann Intern Med, 116, 293, 10.7326/0003-4819-116-4-293

Schiller, 1993, Transesophageal echocardiography in the evaluation of mitral regurgitation. The twenty‐four signs of severe mitral regurgitation, Cardiol Clin, 11, 399, 10.1016/S0733-8651(18)30157-7

Cervera, 2004, Coronary and valvular syndromes and antiphospholipid antibodies, Thromb Res, 114, 501, 10.1016/j.thromres.2004.06.026

Singh, 1999, Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study), Am J Cardiol, 83, 897, 10.1016/S0002-9149(98)01064-9

Brey, 2003, Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002, Lupus, 12, 508, 10.1191/0961203303lu390oa

Cesbron, 1997, Anticardiolipin antibodies and physical disability in the elderly, Ann Intern Med, 126, 1003, 10.7326/0003-4819-126-12-199706150-00024

Chapman, 2002, Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants, J Neurol Sci, 203–204, 81, 10.1016/S0022-510X(02)00271-X

Menon, 1999, A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus, Arthritis Rheum, 42, 735, 10.1002/1529-0131(199904)42:4<735::AID-ANR17>3.0.CO;2-L

Mc Laurin, 2005, Predictors of cognitive dysfunction in patients with systemic lupus erythematosus, Neurology, 64, 297, 10.1212/01.WNL.0000149640.78684.EA

Montalban, 1992, Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus, Neurology, 42, 681, 10.1212/WNL.42.3.681

Tietjen, 1998, Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study, Neurology, 50, 1433, 10.1212/WNL.50.5.1433

Tourbah, 1998, Systemic autoimmune features and multiple sclerosis: a 5‐year follow‐up study, Arch Neurol, 55, 517, 10.1001/archneur.55.4.517

Roussel, 2000, Prevalence and clinical significance of anti‐phospholipid antibodies in multiple sclerosis: a study of 89 patients, J Autoimmun, 14, 259, 10.1006/jaut.2000.0367

Baraczka, 2002, Immunoserological changes in the cerebro‐spinal fluid and serum in systemic lupus erythematosus patients with demyelinating syndrome and multiple sclerosis, Acta Neurol Scand, 105, 378, 10.1034/j.1600-0404.2002.01161.x

Kovacs, 2000, Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature, Ann Rheum Dis, 59, 120, 10.1136/ard.59.2.120

Liou, 1996, Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients, Lupus, 5, 307, 10.1177/096120339600500412

Sanna, 2003, Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies, J Rheumatol, 30, 985

Verrot, 1997, Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy, Am J Med, 103, 33, 10.1016/S0002-9343(97)90046-2

Cimaz, 2002, Prevalence of anti‐cardiolipin, anti‐beta2 glycoprotein I, and anti‐prothrombin antibodies in young patients with epilepsy, Epilepsia, 43, 52, 10.1046/j.1528-1157.2002.00701.x

Shoenfeld, 2004, Features associated with epilepsy in the antiphospholipid syndrome, J Rheumatol, 31, 1344

Diogenes, 2004, Cutaneous manifestations associated with antiphospholipid antibodies, Int J Dermatol, 43, 632, 10.1111/j.1365-4632.2004.01939.x

Sebastiani, 1999, Anticardiolipin and anti‐beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE, Scand J Rheumatol, 28, 344

Ghirardello, 1994, Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome, Ann Rheum Dis, 53, 140, 10.1136/ard.53.2.140

Sachse, 1995, Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group, Rheumatol Int, 15, 23, 10.1007/BF00286765

Naldi, 1993, Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case–control study, Ann Rheum Dis, 52, 219, 10.1136/ard.52.3.219

Vlachoyiannopoulos, 1992, Patients with anticardiolipin antibodies with and without antiphospholipid syndrome: their clinical features and beta 2‐glycoprotein‐I plasma levels, Eur J Clin Invest, 22, 482, 10.1111/j.1365-2362.1992.tb01494.x

Toubi, 2005, Livedo reticularis is a marker for predicting multi‐system thrombosis in antiphospholipid syndrome, Clin Exp Rheumatol, 23, 499

Frances, 1999, Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients, Medicine (Baltimore), 78, 209, 10.1097/00005792-199907000-00001

Gibson, 1997, Antiphospholipid syndrome and the skin, J Am Acad Dermatol, 36, 970, 10.1016/S0190-9622(97)80283-6

Hodak, 2003, Primary anetoderma: a cutaneous sign of antiphospholipid antibodies, Lupus, 12, 564, 10.1191/0961203303lu403oa

Daugas, 2002, Antiphospholipid syndrome nephropathy in systemic lupus erythematosus, J Am Soc Nephrol, 13, 42, 10.1681/ASN.V13142

Tektonidou, 2004, Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long‐term outcome, Arthritis Rheum, 50, 2569, 10.1002/art.20433

Amigo, 1992, Renal involvement in primary antiphospholipid syndrome, J Rheumatol, 19, 1181

Nochy, 1999, The intrarenal vascular lesions associated with primary antiphospholipid syndrome, J Am Soc Nephrol, 10, 507, 10.1681/ASN.V103507

Kincaid‐Smith, 1988, Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy‐related renal failure, Q J Med, 68, 795

Moroni, 2004, Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis, Am J Kidney Dis, 43, 28, 10.1053/j.ajkd.2003.09.011

Stasi, 1994, Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura, Blood, 84, 4203, 10.1182/blood.V84.12.4203.bloodjournal84124203

Diz‐Kucukkaya, 2001, Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study, Blood, 98, 1760, 10.1182/blood.V98.6.1760

Galli, 1994, Anti‐glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies, Thromb Haemost, 71, 571, 10.1055/s-0038-1642484

Macchi, 1997, Anti‐platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia, Br J Haematol, 98, 336, 10.1046/j.1365-2141.1997.2243038.x

Galli, 2003, Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, 101, 1827, 10.1182/blood-2002-02-0441

Galli, 2003, Antiphospholipid antibodies and pregnancy, Best Pract Res Clin Haematol, 16, 211, 10.1016/S1521-6926(02)00094-4

Somers, 2002, Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus, J Rheumatol, 29, 2531

Jennings, 2002, Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods, Br J Haematol, 119, 364, 10.1046/j.1365-2141.2002.03821.x

Arnout, 1999, Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2‐glycoprotein I, Thromb Haemost, 81, 929, 10.1055/s-0037-1614601

Gardiner, 2000, The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant, Br J Haematol, 111, 1230, 10.1111/j.1365-2141.2000.02466.x

Tripodi, 2003, Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity‐purified immunoglobulin with LA activity, Clin Chem, 49, 1608, 10.1373/49.10.1608

Wisloff, 2002, Laboratory diagnosis of the antiphospholipid syndrome, Thromb Res, 108, 263, 10.1016/S0049-3848(02)00400-0

Brandt, 1995, Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH, Thromb Haemost, 74, 1185, 10.1055/s-0038-1649901

Tripodi, 2002, Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA, Thromb Haemost, 88, 583, 10.1055/s-0037-1613259

Jacobsen, 2001, The evaluation of clotting times in the laboratory detection of lupus anticoagulants, Thromb Res, 104, 275, 10.1016/S0049-3848(01)00365-6

1991, Guidelines on testing for the lupus anticoagulant, J Clin Pathol, 44, 885

Greaves, 2000, Guidelines on the investigation and management of the antiphospholipid syndrome, Br J Haematol, 109, 704, 10.1046/j.1365-2141.2000.02069.x

Jacobsen, 2000, The Lupus Ratio test – an interlaboratory study on the detection of Lupus anticoagulants by an APTT‐based, integrated, and semi‐quantitative test. Fifth International Survey of Lupus Anticoagulants – ISLA 5, Thromb Haemost, 83, 704, 10.1055/s-0037-1613896

Simmelink, 2003, A simple method to discriminate between beta2‐glycoprotein I‐ and prothrombin‐dependent lupus anticoagulants, J Thromb Haemost, 1, 740, 10.1046/j.1538-7836.2003.00146.x

Pengo, 2004, A two‐step coagulation test to identify antibeta‐glycoprotein I lupus anticoagulants, J Thromb Haemost, 2, 702, 10.1111/j.1538-7836.2004.00712.x

De Laat, 2004, Beta2‐glycoprotein I‐dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome, Blood, 104, 3598, 10.1182/blood-2004-03-1107

Reber, 1995, Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hemostase et la Thrombose), Thromb Haemost, 73, 444, 10.1055/s-0038-1653795

Favaloro, 2002, Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing, Am J Clin Pathol, 118, 548, 10.1309/JAMH-GDQ6-6BYK-DW6J

Harris, 1990, Special report. The Second International Anti‐cardiolipin Standardization Workshop/the Kingston Anti‐Phospholipid Antibody Study (KAPS) group, Am J Clin Pathol, 94, 476, 10.1093/ajcp/94.4.476

Bahar, 1993, Antibodies to phospholipids and nuclear antigens in non‐pregnant women with unexplained spontaneous recurrent abortions, J Reprod Immunol, 24, 213, 10.1016/0165-0378(93)90076-T

Spadaro, 2000, Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus, Lupus, 9, 56, 10.1177/096120330000900110

2002

Nash, 2004, The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies, J Thromb Haemost, 2, 1077, 10.1111/j.1538-7836.2004.00810.x

Ichikawa, 1999, A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2‐glycoprotein I‐dependent anticardiolipin and anti‐beta2‐glycoprotein I antibodies, Arthritis Rheum, 42, 2461, 10.1002/1529-0131(199911)42:11<2461::AID-ANR25>3.0.CO;2-O

Tincani, 2001, Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations – a cooperative project of the European Antiphospholipid Forum, Thromb Haemost, 86, 575, 10.1055/s-0037-1616089

Carmo‐Pereira, 2003, Value of IgA anticardiolipin and anti‐beta2‐glycoprotein I antibody testing in patients with pregnancy morbidity, Ann Rheum Dis, 62, 540, 10.1136/ard.62.6.540

Selva‐O'Callaghan, 1998, IgA anticardiolipin antibodies – relation with other antiphospholipid antibodies and clinical significance, Thromb Haemost, 79, 282, 10.1055/s-0037-1614978

Bertolaccini, 2001, The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus, J Rheumatol, 28, 2637

Erkan, 2004, Real world experience with aPL‐degree of anticardiolipin antibody variation between assays, Thromb Res, 114, 671

Tajima, 1998, Clinical significance of immunoglobulin A antiphospholipid antibodies: possible association with skin manifestations and small vessel vasculitis, J Rheumatol, 25, 1730

Cucurull, 1999, IgA anticardiolipin and anti‐beta2‐glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus, Am J Med Sci, 318, 55

Galli, 2003, Anti‐beta 2‐glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome, Blood, 102, 2717, 10.1182/blood-2002-11-3334

Reber, 2004, Anti‐beta2‐glycoprotein I antibodies – when and how should they be measured, Thromb Res, 114, 527, 10.1016/j.thromres.2004.06.034

Faden, 1997, Eur J Obstet Gynecol Reprod Biol, 73, 37, 10.1016/S0301-2115(97)02736-X

Lee, 2001, Immunoglobulin A anti‐beta2‐glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death, Am J Obstet Gynecol, 185, 748, 10.1067/mob.2001.117659

Reber, 2002, Inter‐laboratory variability of anti‐beta2‐glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group, Thromb Haemost, 88, 66, 10.1055/s-0037-1613156

Reber, 2004, Proposals for the measurement of anti‐beta2‐glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies, J Thromb Haemost, 2, 1860, 10.1111/j.1538-7836.2004.00910.x

Audrain, 2002, Value of autoantibodies to beta(2)‐glycoprotein 1 in the diagnosis of antiphospholipid syndrome, Rheumatology (Oxford), 41, 550, 10.1093/rheumatology/41.5.550

Marai, 2003, Anti‐cardiolipin and anti‐beta2‐glycoprotein I (beta2GP‐I) antibody assays as screening for anti‐phospholipid syndrome, Hum Antibodies, 12, 57, 10.3233/HAB-2003-12301

Lopez, 2004, Anti‐beta 2‐glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome, Am J Clin Pathol, 121, 142, 10.1309/YVQ6PX76XMYM3J29

Ebeling, 2003, Beta‐2‐glycoprotein I antibodies in patients with thrombosis, Scand J Clin Lab Invest, 63, 111, 10.1080/00365510310002086

Fanopoulos, 1998, High frequency of abnormal levels of IgA anti‐beta2‐glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome, J Rheumatol, 25, 675

Diri, 1999, Antiphospholipid (Hughes’) syndrome in African–Americans: IgA aCL and abeta2 glycoprotein‐I is the most frequent isotype, Lupus, 8, 263, 10.1191/096120399678847812

Greco, 2000, Testing for the antiphospholipid syndrome: importance of IgA anti‐beta 2‐glycoprotein I, Lupus, 9, 33, 10.1177/096120330000900107

Sanmarco, 2001, Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses, Thromb Haemost, 85, 800, 10.1055/s-0037-1615751

Sugi, 2004, Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid‐to‐late pregnancy loss, J Obstet Gynaecol Res, 30, 326, 10.1111/j.1447-0756.2004.00206.x

Bertolaccini, 1998, Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus, J Rheumatol, 25, 1104

Von Landenberg, 2003, Antiprothrombin antibodies are associated with pregnancy loss in patients with the antiphospholipid syndrome, Am J Reprod Immunol, 49, 51, 10.1034/j.1600-0897.2003.01153.x

Horbach, 1996, Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies, Thromb Haemost, 76, 916, 10.1055/s-0038-1650686

Guerin, 1998, Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders, Br J Haematol, 102, 896, 10.1046/j.1365-2141.1998.00876.x

Forastiero, 1997, Relationship of anti beta2‐glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies, Thromb Haemost, 78, 1008, 10.1055/s-0038-1657678

Munoz‐Rodriguez, 2000, Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome, Haematologica, 85, 632

Atsumi, 2000, Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant, Arthritis Rheum, 43, 1982, 10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2

Harris, 2002, Revisiting the anticardiolipin test and its standardization, Lupus, 11, 269, 10.1191/0961203302lu202cr

Wong, 2004, Consensus guidelines on anti‐cardiolipin antibody testing and reporting, Pathology, 36, 63, 10.1080/00313020310001643615

1994, Classification of functional capacity and objective assessment of patients with diseases of the heart, 253

Hojnik, 1996, Heart valve involvement (Libman‐Sacks endocarditis) in the antiphospholipid syndrome, Circulation, 93, 1579, 10.1161/01.CIR.93.8.1579

Hochberg, 1997, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum, 40, 1725, 10.1002/art.1780400928

Tan, 1982, The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum, 25, 1271, 10.1002/art.1780251101

Bizzaro, 1995, EDTA‐dependent pseudothrombocytopenia. Association with antiplatelet and antiphospholipid antibodies, Am J Clin Pathol, 103, 103, 10.1093/ajcp/103.1.103

Arnout, 1996, The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin‐induced thrombocytopenia, Thromb Haemost, 75, 536, 10.1055/s-0038-1650316